Teleflex (NYSE:TFX) Upgraded by Raymond James Financial to “Outperform” Rating

Teleflex (NYSE:TFX) was upgraded by investment analysts at Raymond James Financial from a “market perform” rating to an “outperform” rating in a report issued on Friday. The brokerage presently has a $128.00 price objective on the medical technology company’s stock. Raymond James Financial’s price target indicates a potential upside of 15.86% from the stock’s previous close.

A number of other analysts have also weighed in on TFX. Zacks Research lowered shares of Teleflex from a “hold” rating to a “strong sell” rating in a research note on Monday, March 2nd. Weiss Ratings reiterated a “sell (d)” rating on shares of Teleflex in a research note on Monday, December 29th. Wall Street Zen downgraded shares of Teleflex from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. Royal Bank Of Canada boosted their price objective on shares of Teleflex from $115.00 to $125.00 and gave the stock a “sector perform” rating in a report on Friday, February 27th. Finally, Truist Financial upped their price objective on Teleflex from $120.00 to $135.00 and gave the company a “hold” rating in a research report on Thursday, December 18th. Three analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $139.00.

Teleflex Stock Performance

Teleflex stock opened at $110.48 on Friday. Teleflex has a twelve month low of $100.18 and a twelve month high of $141.91. The company has a quick ratio of 2.01, a current ratio of 2.54 and a debt-to-equity ratio of 0.81. The company has a market capitalization of $4.88 billion, a P/E ratio of -5.38, a PEG ratio of 0.67 and a beta of 0.87. The stock’s 50 day moving average is $108.80 and its 200 day moving average is $116.86.

Teleflex (NYSE:TFX) last announced its quarterly earnings data on Thursday, February 26th. The medical technology company reported $1.93 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.73 by ($1.80). Teleflex had a negative net margin of 30.56% and a positive return on equity of 14.30%. The company had revenue of $569.00 million for the quarter, compared to analysts’ expectations of $912.57 million. During the same quarter in the previous year, the firm posted $3.89 EPS. The firm’s quarterly revenue was down 28.5% compared to the same quarter last year. Teleflex has set its FY 2026 guidance at 6.250-6.550 EPS. On average, equities research analysts predict that Teleflex will post 13.98 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. MassMutual Private Wealth & Trust FSB grew its position in Teleflex by 57.9% in the 3rd quarter. MassMutual Private Wealth & Trust FSB now owns 210 shares of the medical technology company’s stock worth $26,000 after purchasing an additional 77 shares during the period. Banque Cantonale Vaudoise lifted its holdings in shares of Teleflex by 82.5% during the 4th quarter. Banque Cantonale Vaudoise now owns 250 shares of the medical technology company’s stock valued at $31,000 after buying an additional 113 shares during the period. Hantz Financial Services Inc. lifted its holdings in shares of Teleflex by 40.5% during the 4th quarter. Hantz Financial Services Inc. now owns 392 shares of the medical technology company’s stock valued at $48,000 after buying an additional 113 shares during the period. UMB Bank n.a. boosted its stake in shares of Teleflex by 57.1% in the 4th quarter. UMB Bank n.a. now owns 311 shares of the medical technology company’s stock worth $38,000 after buying an additional 113 shares during the last quarter. Finally, Maryland State Retirement & Pension System boosted its stake in shares of Teleflex by 1.5% in the 4th quarter. Maryland State Retirement & Pension System now owns 8,652 shares of the medical technology company’s stock worth $1,056,000 after buying an additional 129 shares during the last quarter. Institutional investors own 95.62% of the company’s stock.

Teleflex Company Profile

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.